- Home
- SRFM vs NRXP Comparison
SRFM vs NRXP Comparison
Compare SRFM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- NRXP
- Stock Information
- Founded
- SRFM 2011
- NRXP 2015
- Country
- SRFM United States
- NRXP United States
- Employees
- SRFM N/A
- NRXP N/A
- Industry
- SRFM Transportation Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- NRXP Health Care
- Exchange
- SRFM Nasdaq
- NRXP Nasdaq
- Market Cap
- SRFM 58.2M
- NRXP 48.5M
- IPO Year
- SRFM 2023
- NRXP N/A
- Fundamental
- Price
- SRFM $4.15
- NRXP $2.99
- Analyst Decision
- SRFM Hold
- NRXP Strong Buy
- Analyst Count
- SRFM 2
- NRXP 3
- Target Price
- SRFM $3.40
- NRXP $31.67
- AVG Volume (30 Days)
- SRFM 399.9K
- NRXP 2.8M
- Earning Date
- SRFM 11-14-2024
- NRXP 03-27-2025
- Dividend Yield
- SRFM N/A
- NRXP N/A
- EPS Growth
- SRFM N/A
- NRXP N/A
- EPS
- SRFM N/A
- NRXP N/A
- Revenue
- SRFM $118,212,000.00
- NRXP N/A
- Revenue This Year
- SRFM $102.41
- NRXP N/A
- Revenue Next Year
- SRFM $47.46
- NRXP N/A
- P/E Ratio
- SRFM N/A
- NRXP N/A
- Revenue Growth
- SRFM 198.78
- NRXP N/A
- 52 Week Low
- SRFM $0.90
- NRXP $1.10
- 52 Week High
- SRFM $9.38
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- SRFM 49.30
- NRXP 49.05
- Support Level
- SRFM $3.45
- NRXP $2.80
- Resistance Level
- SRFM $5.18
- NRXP $3.83
- Average True Range (ATR)
- SRFM 0.59
- NRXP 0.75
- MACD
- SRFM -0.04
- NRXP -0.20
- Stochastic Oscillator
- SRFM 40.46
- NRXP 5.92
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.